Equine Sports Council

Controlled Medications Library

ESC MEDICATION CLASSIFICATIONClass C1 - Strictly Controlled - PE Medical

ESC Medication Library · Revision 4

← Medication library · Compare sanctioning bodies

Medication Facts

Performance enhancing
Conditionally
Total hours to clear
72
Frequently used
Most Prescribed
ESC ID
XYLAZI-0931
Trade names
Rompun, Bay Va
1470
Drug type
Alpha-2 adrenergic agonist
Plasma half-life · hours
1
Equine dosing
0.5-1.1 mg/kg IV or IM
Cmax · peak plasma concentration
250 ng/mL
Tmax · time to peak plasma concentration
0.25
ESC concentration guidance
May not exceed (LDL) Lowest Detectable Level of .05 ng/mL or 50 picograms per mL
Primary withdrawal · hours
48
Washout withdrawal · hours
72
ESC control type
C1 - Strictly Controlled - Restricted - Performance
Medication report required
MED REPORT REQUIRED

Uses & side effects

Drug interactions

In horses, Rompun (xylazine) interactions primarily focus on compounding cardiovascular and respiratory depression, or triggering fatal heart arrhythmias. Because it is a powerful alpha-2 adrenergic agonist, strict caution must be exercised when pairing it with other veterinary medications.1. Risk of Fatal ArrhythmiasPotentiated Sulfonamides: Intravenous administration of sulfonamide antibiotics (such as Trimethoprim/Sulfonamide) in a horse sedated with Rompun is contraindicated. This combination is known to trigger fatal cardiac arrhythmias.Epinephrine / Adrenoceptor Stimulants: Rompun sensitizes the equine heart muscle. Concurrent use with epinephrine or other stimulants can lead to severe ventricular arrhythmias and potential cardiac arrest.2. Synergistic Central Nervous System (CNS) DepressantsRompun significantly increases the effects of other sedatives and anesthetics. When used in combination, veterinary professionals must adjust protocols to prevent respiratory failure or circulatory collapse:Barbiturates: Rompun creates a potent additive effect with barbiturates. Veterinary monitoring is essential to avoid dangerous apnea (interruption of breathing).Other Tranquilizers: Combining Rompun with other tranquilizers (like acepromazine) enhances sedation but increases the risk of severe low blood pressure and deep CNS depression.Inhalant Anesthetics: Rompun reduces the amount of gas anesthesia required, necessitating careful monitoring to prevent over-anesthetization.3. Common Veterinary CombinationsIn professional settings, Rompun is often combined with other agents to achieve specific clinical outcomes:Ketamine: Rompun is frequently used as a pre-medication before ketamine induction to provide the muscle relaxation necessary for a smooth transition into anesthesia.Opioids: Combining Rompun with opioids like butorphanol can create a profound sedative and analgesic effect for standing procedures.4. Reversal AgentsIf a horse experiences severe cardiovascular depression from Rompun, veterinarians may use specific alpha-2 antagonists to reverse its effects. Common reversal agents include:YohimbineAtipamezoleTolazolineDue to the risks of respiratory depression, heart arrhythmias, and other severe side effects, all administration and monitoring of Rompun must be performed by a licensed veterinarian. If a horse is experiencing a medical emergency, a local equine practitioner or emergency veterinary clinic should be contacted immediately.

Contraindications

xylazine, gabapentin, detomidine, romifidine, Butorphanol, Torbugesic, Pentazocine, Naltrexone, Dextropropoxyphene

Government Numbers

Rompun xylazine injection, 100 mg/mL: NADA 047-956; NDC 17033-099-05 (50 mL). Labeler: Dechra Vet Products, LLC. IV and IM routes are specified for horses. Identifiers apply to this formulation. Reviewed September 18, 2026. Full label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38632b3f-293e-42c9-be78-81909570f21a

Sanctioning-body comparison

Plasma only. Compare published competition guidance for this medication. ESC guidance remains in Medication Facts above. A dosing guideline, withdrawal recommendation and laboratory detection threshold are different measures.

Sources reviewed September 23, 2026. “Not verified” means a gap in this comparison, not zero tolerance or permission. Doses describe the cited rules; your veterinarian must determine treatment and withdrawal.

Published guidance by organization
OrganizationPublished dose & routePlasma concentrationWithdrawal / timingControl / penalty class
AQHA Show HorsesShow rules · 2026 handbook
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
APHA Paint Show HorsesShow rules · 2026 Rule Book
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
ARCI Model RulesRacing model · Rules 15 / UCG 20.0 / CTMS 4.2.1
Conditions & sources

ARCI model comparison only; no state-specific rule is substituted. Schedule timing is tied to its stated regimen and is not a clearance guarantee.

CTMS 4.2.1; UCG 20.0 PDF p. 56

Reviewed 2026-09-23

200 mg IV200 pg/mL48 h withdrawal guidelineDrug Class 3 · Penalty Class B. Controlled therapeutic schedule; classification shown below.
USEFNational Therapeutic Substance Provisions · 2026 + July amendment
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.